Improving The Treatment For Childhood Cancer: Neuroblastoma As A Model
Funder
National Health and Medical Research Council
Funding Amount
$5,029,092.00
Summary
One in three children with cancer still die of their disease, and side-effects of treatment are considerable. Over the past 15 years, the Chief Investigators have established themselves as a leading international research group in child cancer and have successfully applied their laboratory-based discoveries to improve the clinical management of children with malignant diseases. In particular, key advances have been made in basic cell biology, molecular biology and in defining clinically relevant ....One in three children with cancer still die of their disease, and side-effects of treatment are considerable. Over the past 15 years, the Chief Investigators have established themselves as a leading international research group in child cancer and have successfully applied their laboratory-based discoveries to improve the clinical management of children with malignant diseases. In particular, key advances have been made in basic cell biology, molecular biology and in defining clinically relevant molecular targets and prognostic indicators for the child cancer, neuroblastoma, the commonest solid tumour in young children. These findings have been made possible by the team assembling, over recent years, an extensive and unique range of in vitro and in vivo model systems, together with a large bank of clinical neuroblastoma specimens. In this research program, the team members propose an experimental approach that will continue their studies, focussing on cancer initiation and better target identification within cancer cells, leading to the development of effective and non-toxic novel compounds, possibly prevention strategies,and introduction of novel therapies into clinical trial.Read moreRead less
Genetic And Bioinformatic Analysis Of Complex Human Diseases
Funder
National Health and Medical Research Council
Funding Amount
$8,752,567.00
Summary
Some human diseases are common in families; examples include prostate cancer, blood cancers, epilepsy and diabetes. Therefore, close relatives of individuals with a disease have an increased risk of being affected by this disease, implying a genetic basis. Finding the cause of these diseases is difficult, we will be developing novel approaches to the identification of genes responsible for these diseases. This is the first step towards the development of treatments for affected individuals.
The genome project has opened the path for the study of diseases using genetics. This approach is still quite recent in human and mammalian biology. It requires a large amount of input from statisticians and computer scientists as well as from the biologists and clinicians working on the disease. The team is looking for genes causing complex genetic diseases and use human populations and families as well as mouse models of human diseases. This includes modifiers of cancer development and respons ....The genome project has opened the path for the study of diseases using genetics. This approach is still quite recent in human and mammalian biology. It requires a large amount of input from statisticians and computer scientists as well as from the biologists and clinicians working on the disease. The team is looking for genes causing complex genetic diseases and use human populations and families as well as mouse models of human diseases. This includes modifiers of cancer development and response to infectious disease as well as deafness and autoimmune diseases.Read moreRead less
Malaria: From Target Identification And Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$5,276,440.00
Summary
The team brings together a number of experts in various aspects of malaria, vaccines and drug design to develop new therapeutic approaches to control of one of the world�s major infectious diseases. Recent developments such as the complete sequence of every malaria gene provides an unparalleled opportunity to use a number of powerful new techniques in biology to identify vulnerabilities in the parasite that may be targeted. Members of the team include Professor von Itzstein who was responsible f ....The team brings together a number of experts in various aspects of malaria, vaccines and drug design to develop new therapeutic approaches to control of one of the world�s major infectious diseases. Recent developments such as the complete sequence of every malaria gene provides an unparalleled opportunity to use a number of powerful new techniques in biology to identify vulnerabilities in the parasite that may be targeted. Members of the team include Professor von Itzstein who was responsible for the design of the anti-flu drug Relenza, Professor Ross Coppel who is a pioneer in the application of molecular biology to the study of malaria, and Drs Cooke and Plebanski, exciting and talented young scientists who already have made highly significant and important contributions to our understanding of how malaria parasites function and cause disease. Success in this research program has the capacity to save millions of lives each year by preventing the deadly toll of this important human scourge.Read moreRead less
Proteases, Their Inhibitors And Receptors In Degenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$5,843,388.00
Summary
Many of the themes of this program are aimed at understanding the molecular basis of several important degenerative diseases that in particular affect the ageing population. These include osteoporosis, arthritis, periodontal disease, wasting diseases of muscle and inherited disorders such as antitrypsin deficiency. The five CI’s on this application have formed a collaborative network since 1996. Dr Whisstock is a bioinformatician and structural biologist with a research focus on the serpin super ....Many of the themes of this program are aimed at understanding the molecular basis of several important degenerative diseases that in particular affect the ageing population. These include osteoporosis, arthritis, periodontal disease, wasting diseases of muscle and inherited disorders such as antitrypsin deficiency. The five CI’s on this application have formed a collaborative network since 1996. Dr Whisstock is a bioinformatician and structural biologist with a research focus on the serpin superfamily of protease inhibitors and their protease partners. He is currently the scientific director of the Victorian Bioinformatics Consortium and an NHMRC Senior Research Fellow. Dr Bird is an NHMRC Senior Research Fellow who discovered the intracellular branch of the serpin superfamily and formulated the hypothesis that describes their function. A-Prof Mackie is a world expert in the field of musculoskeletal biology and pathology. Dr Bottomley is a Senior Logan Fellow and RD Wright Fellow whose research focuses upon how proteins misfold and lead to disease. Dr Pike is an enzymologist whose research area encompasses a wide range of bacterial and mammalian proteases involved in the pathology of human disease. Each individual in this team brings different skills which makes this a very important and powerful collaboration. The research is extensive and involves protein folding, enzyme kinetics, molecular modelling, structural biology, bioinformatics, cell biology and pathology, enzyme kinetics and drug design. Collectively the CI’s have a total of 154 papers since 1998, of which a third include two or more of the CI’s as co-authors. Currently the team holds over >$5 million in grant funding. The team is augmented by four P.I.s: Dr Buckle is a talented structural biologist; Dr Scott is a molecular cell biologist who holds an NHMRC CJ Martin Fellow; Dr Garcia de la Banda is a computer scientist based at Monash and Dr Grigoryev is a world expert in chromatin condensation based at Penn State University (USA).Read moreRead less
Generating The Evidence For New Strategies To Combat Cardiovascular Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$12,809,917.00
Summary
The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour combating heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and the world. While there are many established treatment and prevention strategies there remains great potential for further advances to avert large numbers of deaths and serious disabling outcomes. This Program will provide new information that will give patien ....The Program brings together clinicians, epidemiologists and statisticians in a unique endeavour combating heart attack and stroke. For the foreseeable future, these conditions will remain leading causes of death and disease in Australia and the world. While there are many established treatment and prevention strategies there remains great potential for further advances to avert large numbers of deaths and serious disabling outcomes. This Program will provide new information that will give patients, doctors, consumers and policy makers new options for disease prevention.Read moreRead less
A Program Of Research Addressing The Transition From Health To Advanced Cardiovascular Disease.
Funder
National Health and Medical Research Council
Funding Amount
$13,017,057.00
Summary
Cardiovascular disease (CVD) is the major cause of death and disability in Australia and worldwide. This burden will increase without new knowledge. We will address knowledge gaps that delay more effective prevention and control. Our team has a strong track record of influencing clinical practice of CVD prevention, treatment and technology transfer. For many, the first indication of a heart problem is sudden heart attack or death. By understanding mechanisms we aim to develop new tests and treat ....Cardiovascular disease (CVD) is the major cause of death and disability in Australia and worldwide. This burden will increase without new knowledge. We will address knowledge gaps that delay more effective prevention and control. Our team has a strong track record of influencing clinical practice of CVD prevention, treatment and technology transfer. For many, the first indication of a heart problem is sudden heart attack or death. By understanding mechanisms we aim to develop new tests and treatments that prevent heart attack, heart failure and other serious consequences of atherosclerosis.Read moreRead less
Patient Safety: Enabling And Supporting Change For A Safer And More Effective Health System
Funder
National Health and Medical Research Council
Funding Amount
$8,878,409.00
Summary
Internationally, patient safety is a growing concern. Patient harm occurs in 10% of hospital admissions. A million adverse events occur in general practice each year in Australia. Overseas data reports that patients receive recommended care only 50% of the time. We will significantly advance this work by investigating how and why this ccurs, with a focus on the roles of teamwork, safe medication use and the application of information technology to support improved decision-making.